Have a personal or library account? Click to login
Alpha adrenergic receptors in clinical practice – Present and future Cover

Alpha adrenergic receptors in clinical practice – Present and future

Open Access
|Jan 2023

References

  1. 1. Rizalar FS, Roosen DA, Haucke V. A Presynaptic Perspective on Transport and Assembly Mechanisms for Synapse Formation. Neuron. 2021;109(1):27-41. doi:10.1016/j.neuron.2020.09.03833098763
  2. 2. Perez DM. α1-Adrenergic Receptors in Neurotransmission, Synaptic Plasticity, and Cognition. Frontiers in Pharmacology. 2020;11. https://www.frontiersin.org/articles/10.3389/fphar.2020.58109810.3389/fphar.2020.581098755305133117176
  3. 3. Szabadi E. Introduction to Neuropsychopharmacology. Br J Clin Pharmacol. 2009;68(6):965. doi:10.1111/j.1365-2125.2009.03529.x
  4. 4. Nguyen PV, Connor SA. Noradrenergic Regulation of Hippocampus-Dependent Memory. Cent Nerv Syst Agents Med Chem. 2019;19(3):187-196. doi:10.2174/187152491966619071916363231749419
  5. 5. Ordway GA, Schwartz MA, Frazer A. Brain Norepinephrine: Neurobiology and Therapeutics. Cambridge University Press; 2007.10.1017/CBO9780511544156
  6. 6. Langer SZ. α2-Adrenoceptors in the treatment of major neuropsychiatric disorders. Trends Pharmacol Sci. 2015;36(4):196-202. doi:10.1016/j.tips.2015.02.00625771972
  7. 7. Kobayashi M, Sasabe T, Shiohama Y, Koshikawa N. Activation of alpha1-adrenoceptors increases firing frequency through protein kinase C in pyramidal neurons of rat visual cortex. Neurosci Lett. 2008;430(2):175-180. doi:10.1016/j.neulet.2007.10.04718061348
  8. 8. Velásquez-Martinez MC, Vázquez-Torres R, Jiménez-Rivera CA. Activation of alpha1-adrenoceptors enhances glutamate release onto ventral tegmental area dopamine cells. Neuroscience. 2012;216:18-30. doi:10.1016/j.neuroscience.2012.03.056380908022542873
  9. 9. Salgado H, Garcia-Oscos F, Patel A, et al. Layer-specific noradrenergic modulation of inhibition in cortical layer II/III. Cereb Cortex. 2011;21(1):212-221. doi:10.1093/cercor/bhq081300057120466749
  10. 10. Bellinger DL, Lorton D. Autonomic regulation of cellular immune function. Auton Neurosci. 2014;182:15-41. doi:10.1016/j.autneu.2014.01.00624685093
  11. 11. RxList - The Internet Drug Index for prescription drug information, interactions, and side effects. RxList. Accessed October 7, 2022. https://www.rxlist.com/
  12. 12. Alpha 1 Adrenergic Receptor Antagonists. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http://www.ncbi.nlm.nih.gov/books/NBK548719/
  13. 13. Datta D, Yang ST, Galvin VC, et al. Noradrenergic α1-Adrenoceptor Actions in the Primate Dorsolateral Prefrontal Cortex. J Neurosci. 2019;39(14):2722-2734. doi:10.1523/JNEUROSCI.2472-18.2019644599330755491
  14. 14. Feighner JP. Mechanism of action of antidepressant medications. J Clin Psychiatry. 1999;60 Suppl 4:4-11; discussion 12-13.10.4088/JCP.v60n1204
  15. 15. Kovich H, DeJong A. Common Questions About the Pharmacologic Management of Depression in Adults. Am Fam Physician. 2015;92(2):94-100.
  16. 16. Born GVR, Banks P. Hugh Blaschko, 4 January 1900 - 18 April 1993. Biographical Memoirs of Fellows of the Royal Society. 1996;42:40-60. doi:10.1098/rsbm.1996.0004
  17. 17. Rubin RP. Hermann (Hugh) Blaschko (1900-1993): His fundamental contributions to biochemical pharmacology and clinical medicine. J Med Biogr. 2019;27(3):179-183. doi:10.1177/096777201770309130848165
  18. 18. Taylor BN, Cassagnol M. Alpha Adrenergic Receptors. StatPearls Publishing; 2022. https://www.ncbi.nlm.nih.gov/books/NBK539830/
  19. 19. Haj-Dahmane S, Shen RY. Chronic stress impairs α1-adrenoceptor-induced endocannabinoid-dependent synaptic plasticity in the dorsal raphe nucleus. J Neurosci. 2014;34(44):14560-14570. doi:10.1523/JNEUROSCI.1310-14.2014421206125355210
  20. 20. Paudel S, Wang S, Kim E, et al. Design, Synthesis, and Functional Evaluation of 1, 5-Disubstituted Tetrazoles as Monoamine Neurotransmitter Reuptake Inhibitors. Biomol Ther (Seoul). 2022;30(2):191-202. doi:10.4062/biomolther.2021.119890245934789584
  21. 21. Hamon M, Blier P. Monoamine neurocircuitry in depression and strategies for new treatments. Prog Neuropsychopharmacol Biol Psychiatry. 2013;45:54-63. doi:10.1016/j.pnpbp.2013.04.00923602950
  22. 22. Velásquez-Martínez MC, Vázquez-Torres R, Rojas LV, Sanabria P, Jiménez-Rivera CA. Alpha-1 adrenoreceptors modulate GABA release onto ventral tegmental area dopamine neurons. Neuropharmacology. 2015;88:110-121. doi:10.1016/j.neuropharm.2014.09.002425251825261018
  23. 23. Oberbeck R, Schmitz D, Wilsenack K, et al. Adrenergic modulation of survival and cellular immune functions during polymicrobial sepsis. Neuroimmunomodulation. 2004;11(4):214-223. doi:10.1159/00007843915249727
  24. 24. Pongratz G, Straub RH. The sympathetic nervous response in inflammation. Arthritis Res Ther. 2014;16(6):504. doi:10.1186/s13075-014-0504-2439683325789375
  25. 25. Starke K, Göthert M, Kilbinger H. Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol Rev. 1989;69(3):864-989. doi:10.1152/physrev.1989.69.3.8642568648
  26. 26. Uys MM, Shahid M, Harvey BH. Therapeutic Potential of Selectively Targeting the α2C-Adrenoceptor in Cognition, Depression, and Schizophrenia—New Developments and Future Perspective. Frontiers in Psychiatry. 2017;8. https://www.frontiersin.org/articles/10.3389/fpsyt.2017.0014410.3389/fpsyt.2017.00144555805428855875
  27. 27. Brosda J, Jantschak F, Pertz HH. α2-Adrenoceptors are targets for antipsychotic drugs. Psychopharmacology (Berl). 2014;231(5):801-812. doi:10.1007/s00213-014-3459-824488407
  28. 28. Cottingham C, Wang Q. α2 adrenergic receptor dysregulation in depressive disorders: implications for the neurobiology of depression and antidepressant therapy. Neurosci Biobehav Rev. 2012;36(10):2214-2225. doi:10.1016/j.neubiorev.2012.07.011350831022910678
  29. 29. Srivastava AB, Mariani JJ, Levin FR. New directions in the treatment of opioid withdrawal. Lancet. 2020;395(10241):1938-1948. doi:10.1016/S0140-6736(20)30852-7738566232563380
  30. 30. Holzer P, Holzer-Petsche U. Pharmacology of inflammatory pain: local alteration in receptors and mediators. Dig Dis. 2009;27(0 1):24-30. doi:10.1159/000268118437082920203494
  31. 31. Ju JY, Kim KM, Lee S. Effect of preoperative administration of systemic alpha-2 agonists on postoperative pain: a systematic review and meta-analysis. Anesth Pain Med (Seoul). 2020;15(2):157-166. doi:10.17085/apm.2020.15.2.157771382633329808
  32. 32. Spieth PP, Geier C, Reske AW. Alpha-2 agonists: back to the future of human anesthesia? Minerva Anestesiol. 2015;81(10):1058-1060.
  33. 33. Zhang X, Bai X. New therapeutic uses for an alpha2 adrenergic receptor agonist--dexmedetomidine in pain management. Neurosci Lett. 2014;561:7-12. doi:10.1016/j.neulet.2013.12.03924373989
  34. 34. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev. 2000;52(4):595-638.10.1016/S0031-6997(24)01470-4
  35. 35. Kerage D, Sloan EK, Mattarollo SR, McCombe PA. Interaction of neurotransmitters and neurochemicals with lymphocytes. Journal of Neuroimmunology. 2019;332:99-111. doi:10.1016/j.jneuroim.2019.04.00630999218
  36. 36. Bergquist J, Tarkowski A, Ekman R, Ewing A. Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop. Proceedings of the National Academy of Sciences. 1994;91(26):12912-12916. doi:10.1073/pnas.91.26.12912
  37. 37. Cosentino M, Fietta AM, Ferrari M, et al. Human CD4+CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop. Blood. 2007;109(2):632-642. doi:10.1182/blood-2006-01-02842316985181
  38. 38. Yamaguchi I, Kopin IJ. Plasma catecholamine and blood pressure responses to sympathetic stimulation in pithed rats. American Journal of Physiology-Heart and Circulatory Physiology. 1979;237(3):H305-H310. doi:10.1152/ajpheart.1979.237.3.H305474768
  39. 39. Jang HS, Kim J, Padanilam BJ. Renal sympathetic nerve activation via α2-adrenergic receptors in chronic kidney disease progression. Kidney Res Clin Pract. 2019;38(1):6-14. doi:10.23876/j.krcp.18.0143648196930831675
  40. 40. Van Amersfoort ES, Van Berkel TJ, Kuiper J. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev. 2003 Jul;16(3):379-414. doi: 10.1128/CMR.16.3.379-414.2003. PMID: 12857774; PMCID: PMC164216.16421612857774
  41. 41. Ferreira J. The Theory is Out There: The Use of ALPHA-2 Agonists in Treatment of Septic Shock. Shock. 2018;49(4):358-363. doi:10.1097/SHK.000000000000097928858141
  42. 42. Anwar MS, Iskandar MZ, Parry HM, Doney AS, Palmer CN, Lang CC. The future of pharmacogenetics in the treatment of heart failure. Pharmacogenomics. 2015;16(16):1817-1827. doi:10.2217/pgs.15.12026555119
DOI: https://doi.org/10.2478/amma-2022-0030 | Journal eISSN: 2668-7763 | Journal ISSN: 2668-7755
Language: English
Page range: 145 - 149
Submitted on: Nov 28, 2022
Accepted on: Dec 7, 2022
Published on: Jan 7, 2023
Published by: University of Medicine, Pharmacy, Science and Technology of Targu Mures
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2023 Patrick Lechsner, Erika-Gyongyi Ban, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution 4.0 License.